复方苦参注射液联合紫杉醇和替吉奥治疗晚期胃癌的临床疗效观察  

Observation on Clinical Effects of Compound Kushen Injection Combined with Paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsules in the Treatment for Advanced Gastric Cancer

作　　者：房伟[1] 马云涛[1] 马世勋[1] 李渊[1] 李一平[1] 苗长丰 FANG Wei;MA Yuntao;MA Shixun;LI Yuan;LI Yiping;MIAO Changfeng(Gansu Provincial Hospital,Lanzhou 730030,China)

机构地区：[1]甘肃省人民医院,甘肃兰州730030

出　　处：《西部中医药》2021年第4期100-104,共5页Western Journal of Traditional Chinese Medicine

基　　金：甘肃省自然科学基金(1508RJZA043)。

摘　　要：目的:观察复方苦参注射液联合紫杉醇(PTX)和替吉奥(S-1)治疗晚期胃癌的短期疗效和毒副反应。方法:选择晚期胃癌患者50例,随机分为观察组和对照组,每组25例。观察组:紫杉醇135 mg/m2,静脉滴注,第1天;替吉奥胶囊每日80 mg,口服,每日2次,1~14天,停药1周;复方苦参注射液12 mL,加入200 mL0.9%氯化钠注射液稀释,静脉滴注,1~14天,停药1周。对照组:紫杉醇135 mg/m2,静脉滴注,第1天;替吉奥胶囊每日80 mg,口服,每日2次,1~14天,停药1周。21天为1个周期,每例至少完成4个治疗周期。两组疗效评价参照WHO近期疗效评价标准;不良反应评价参照抗癌药物毒副反应的分度标准。结果:观察组有效率为56.0%(14/25),临床受益率为84.0%(21/25);对照组有效率为44.0%(11/25),临床受益率为72.0%(18/25)。两组间有效率及临床受益率比较,差异均无统计学意义(P>0.05)。两组患者化疗后各种不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:复方苦参注射液联合紫杉醇和替吉奥治疗晚期胃癌具有良好的临床疗效,且不增加化疗药物不良反应。Objective:To observe short-term effects and toxic reaction of compound Kushen injection combined with paclitaxel(PTX)and tegafur gimeracil oteracil potassium capsules(S-1)in the treatment for advanced gastric cancer.Methods:Fifty patients were randomized into the observation group and the control group,25 cases each group.The observation group:PTX,135 mg/m2,intravenous dripping,at the first day;S-180 mg/d,oral administration,bid,1~14 days,drug withdrawal for one week;compound Kushen injection,12 mL,adding 200 mL,0.9%sodium chloride injection to dilute,intravenous dripping,1~14 days,drug withdrawal for one week.The control group:PTX,135 mg/m2,intravenous dripping,at the first day;S-180 mg/d,oral administration,bid,1~14 days,drug withdrawal for one week.21 days were one course,each case must finish four therapeutic cycles at least.Clinical effects were assessed in light of evaluation criteria for short-term efficacy of WHO;toxic reactions were assessed according to classification criteria for toxic reaction of anti-cancer drugs(WHO).Results:The effective rate of the observation group was 56.0%(14/25),clinical benefit rate was 84.0%(21/25);the effective rate of the control group was 44.0%(11/25),clinical benefit rate was 72.0%(18/25).The difference had no statistical meaning in the comparisons of the effective rate and clinical benefit rate between both groups.The difference had no statistical meaning in the comparisons of the incidences of adverse reaction after chemotherapy between both groups(P>0.05).Conclusion:Compound Kushen injection combined with PTX and S-1 could gain better effects in the treatment for advanced gastric cancer,and it would not arouse adverse reaction of chemotherapeutic agents.

关 键 词：晚期胃癌 紫杉醇 替吉奥 复方苦参注射液 临床疗效 

分 类 号：R735[医药卫生—肿瘤]